293 related articles for article (PubMed ID: 23788085)
1. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
Kuliczkowski W; Urbaniak J; Hallén J; Woźniak M; Poloński L; Mysiak A; Atar D; Zembala M; Serebruany V
Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
[TBL] [Abstract][Full Text] [Related]
2. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.
Nilsson L; Hallén J; Atar D; Jonasson L; Swahn E
Heart; 2012 Jan; 98(1):31-6. PubMed ID: 21727201
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
[TBL] [Abstract][Full Text] [Related]
4. Left anterior descending coronary artery flow after primary angioplasty in acute anterior ST-elevation myocardial infarction: how much flow is needed for left ventricular functional recovery?
Sharif D; Sharif-Rasslan A; Khalil A; Rosenschein U
Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):223-8. PubMed ID: 24493865
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of invasive treatment and the occurrence of cardiac rupture in acute ST-elevation myocardial infarction.
Ptaszyńska-Kopczyńska K; Sobolewska D; Kożuch M; Dobrzycki S; Sobkowicz B; Hirnle T; Musiał WJ; Kamiński KA
Kardiol Pol; 2011; 69(8):795-800. PubMed ID: 21850621
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
Ochała A; Smolka G; Wojakowski W; Gabrylewicz B; Garbocz P; Tendera M
Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
[TBL] [Abstract][Full Text] [Related]
8. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
9. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of plasma renin activity in acute myocardial infarction patients treated with primary percutaneous coronary interventions].
Stryjewski PJ; Pietrucha AZ; Stopyra K; Nessler B; Kruszelnicka O; Gackowski A; Konduracka E; Sztefko K; Badacz L; Nessler J
Przegl Lek; 2011; 68(7):354-8. PubMed ID: 22010471
[TBL] [Abstract][Full Text] [Related]
11. Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction.
Jia ZB; Tian H; Kang K; Miao HZ; Liu KY; Jiang SL; Wang LP
Transpl Immunol; 2014 May; 30(4):149-58. PubMed ID: 24727088
[TBL] [Abstract][Full Text] [Related]
12. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
Wang W; Zhang HT; Yang XL
J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
[TBL] [Abstract][Full Text] [Related]
13. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
[TBL] [Abstract][Full Text] [Related]
14. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.
Yan HB; Li SY; Song L; Wang J; Wu Z; Chi YP; Zheng B; Zhao HJ; Li QX; Zhang XJ; Li WZ
Chin Med J (Engl); 2010 Apr; 123(7):877-83. PubMed ID: 20497681
[TBL] [Abstract][Full Text] [Related]
15. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction.
Wang KF; Huang PH; Chiang CH; Hsu CY; Leu HB; Chen JW; Lin SJ
Coron Artery Dis; 2013 Jan; 24(1):23-8. PubMed ID: 23151854
[TBL] [Abstract][Full Text] [Related]
17. [Effect of left ventricular ejection fraction on clinical long-term follow-up outcomes in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Wang CH; Xie XJ; Fang Q; Zhang SY; Fang ZJ; Jiang XF; Xie HZ; Liu ZY; Shen ZJ
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):265-8. PubMed ID: 21418873
[TBL] [Abstract][Full Text] [Related]
18. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction.
Zhang H; Tian NL; Hu ZY; Wang F; Chen L; Zhang YJ; Chen SL
Chin Med J (Engl); 2012 May; 125(10):1713-9. PubMed ID: 22800889
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
20. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
